Therapeutic targets and investigated treatments for Ataxia-Telangiectasia

References

• Savitsky K, Bar-Shira A, Gilad S, et al. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science. 1995;268:1749–1753.
   PubMed Web of Science ®Google Scholar
• Boder E, Sedgwick RP Ataxia-telangiectasia; a familial syndrome of progressive cerebellar ataxia, oculocutaneous telangiectasia and frequent pulmonary infection. A Preliminary Report on 7 children, an autopsy, and a case history: USC Med Bull; 1957.
   Google Scholar
• Biemond A. [Acute ataxia in children]. Ned Tijdschr Geneeskd. 1957;101:529–532.
   PubMedGoogle Scholar
• Sedgewick RP, Boder E. Ataxia-telangiectasia. In: Vinken BG, editor. Handbook of clinical neurology. Vol. 14. Amsterdam: North Holland Publishers; 1972. p. 267–339.
   Google Scholar
• Taylor AMR, Byrd PJ. Molecular pathology of ataxia telangiectasia. J Clin Pathol. 2005;58:1009–1015.
   PubMed Web of Science ®Google Scholar
• Verhagen MMM, Martin JJ, Van Deuren M, et al. Neuropathology in classical and variant ataxia-telangiectasia. Neuropathology. 2012;32:234–244. .
   PubMed Web of Science ®Google Scholar
• Mcfarlin DE, Waldmann TA, Strober W. Ataxia-telangiectasia. Medicine. 1972;51:281.
   PubMed Web of Science ®Google Scholar
• Peterson RD, Kelly WD, Good RA. Ataxia-telangiectasia: Its association with a defective thymus, immunological-deficiency disease, and malignancy. Lancet 1964; 13:1189–1193
   PubMed Web of Science ®Google Scholar
• Schroeder SA, Zielen S. Infections of the respiratory system in patients with ataxia-telangiectasia. Pediatr Pulm. 2014;49:389–399. .
   PubMed Web of Science ®Google Scholar
• Bhatt JM, Bush A. Microbiological surveillance in lung disease in ataxia telangiectasia. Eur Respir J. 2014;43:1797–1801.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Collaco JM, Crawford TO, et al. Elevated serum IL-8 levels in ataxia telangiectasia. J Pediatr-US. 2010;156:682–U213.
   PubMed Web of Science ®Google Scholar
• Hartlova A, Erttmann SF, Raffi FAM, et al. DNA damage primes the type I interferon system via the cytosolic DNA sensor STING to promote anti-microbial innate immunity. Immunity. 2015;42:332–343.
   PubMed Web of Science ®Google Scholar
• Erttmann SF, Hartlova A, Sloniecka M, et al. Loss of the DNA damage repair kinase ATM impairs inflammasome-dependent anti-bacterial innate immunity. Immunity. 2016;45:106–118.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Gower WA, Rothblum-Oviatt C, et al. Evaluation and management of pulmonary disease in ataxia-telangiectasia. Pediatr Pulmonol. 2010;45:847–859.
   PubMed Web of Science ®Google Scholar
• McGrath-Morrow SA, Lederman HM, Aherrera AD, et al. Pulmonary function in children and young adults with ataxia telangiectasia. Pediatr Pulm. 2014;49:84–90.
   PubMed Web of Science ®Google Scholar
• Spector BD, Filipovich AH, Perry GSI, et al. Epidemiology of cancer in ataxia-telangiectasia. In: Bridges BA, Harnden DG, editors. Ataxia telangiectasia: a cellular and molecular link between cancer, neuropathology and immune deficiency. New York: Wiley; 1982. p. 103–138.
   Google Scholar
• Lavin MF, Gueven N, Bottle S, et al. Current and potential therapeutic strategies for the treatment of ataxia-telangiectasia. Brit Med Bull. 2007;81-82:129–147.
   PubMed Web of Science ®Google Scholar
• Davis MM, Gatti RA, Sparks RS. Neoplasia and chromosomal breakage in ataxia-telangiectasia. In: Gatti R, Harnden DG, editors. Ataxia telangiectasia: a cellular and molecular link between cancer, neuropathology and immune deficiency. New York: Alan R. Liss, Inc; 1985. p. 197–203.
   Google Scholar
• Barlow C, Hirotsune S, Paylor R, et al. ATM-deficient mice: a paradigm of ataxia telangiectasia. Cell. 1996;86:159–171.
   PubMed Web of Science ®Google Scholar
• Xu Y, Baltimore D. Dual roles of ATM in the cellular response to radiation and in cell growth control. Gene Dev. 1996;10:2401–2410.
   PubMed Web of Science ®Google Scholar
• Hecht F, Hecht BK. Cancer in ataxia-telangiectasia patients. Cancer Genet Cytogen. 1990;46:9–19.
   PubMedGoogle Scholar
• Swift M, Morrell D, Massey RB, et al. Incidence of cancer in 161 families affected by ataxia-telangiectasia. New Engl J Med. 1991;325:1831–1836.
   PubMed Web of Science ®Google Scholar
• Bhatt JM, A B, van Gerven M, et al. ERS statement on the multidisciplinary respiratory management of ataxia telangiectasia. Eur Respir Rev. 2015;24:565–581 .
   PubMed Web of Science ®Google Scholar
• Waldmann TA, Mcintire KR. Serum-alpha-fetoprotein levels in patients with ataxia-telangiectasia. Lancet. 1972;2:1112.
   PubMed Web of Science ®Google Scholar
• Jung CG, Kim HJ, Kawaguchi M, et al. Homeotic factor ATBF1 induces the cell cycle arrest associated with neuronal differentiation. Development. 2005;132:5137–5145.
   PubMed Web of Science ®Google Scholar
• Schalch DS, McFarlin DE, Barlow MH. An unusual form of diabetes mellitus in ataxia telangiectasia. N Engl J Med. 1970;282:1396–1402.
   PubMed Web of Science ®Google Scholar
• Srisirirojanakorn N, Finegold MJ, Gopalakrishna GS, et al. Hepatic veno-occlusive disease in ataxia-telangiectasia. J Pediatr. 1999;134:786–788.
   PubMed Web of Science ®Google Scholar
• Amromin GD, Boder E, Teplitz R. Ataxia-telangiectasia with a 32 year survival. A clinicopathological report. J Neuropathol Exp Neurol. 1979;38:621–643.
   PubMed Web of Science ®Google Scholar
• Caballero T, Caba-Molina M, Salmeron J, et al. Nonalcoholic steatohepatitis in a patient with ataxia-telangiectasia. Case Reports Hepatol. 2014;2014:761250.
   PubMedGoogle Scholar
• Weiss B, Krauthammer A, Soudack M, et al. Liver disease in pediatric patients with ataxia telangiectasia: a novel report. J Pediatr Gastroenterol Nutr. 2016;62:550–555.
   PubMed Web of Science ®Google Scholar
• Mercer JR, Cheng KK, Figg N, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res. 2010;107:1021–1031.
   PubMed Web of Science ®Google Scholar
• Bar RS, Levis WR, Rechler MM, et al. Extreme insulin resistance in ataxia telangiectasia - defect in affinity of insulin receptors. New Engl J Med. 1978;298:1164–1171.
   PubMed Web of Science ®Google Scholar
• Yang DQ, Kastan MB. Participation of ATM in insulin signalling through phosphorylation of eIf-4E-binding protein 1. Nat Cell Biol. 2000;2:893–898.
   PubMed Web of Science ®Google Scholar
• Schneider JG, Finck BN, Ren J, et al. ATM-dependent suppression of stress signaling reduces vascular disease in metabolic syndrome. Cell Metab. 2006;4:377–389.
   PubMed Web of Science ®Google Scholar
• Takagi M, Uno H, Nishi R, et al. ATM regulates adipocyte differentiation and contributes to glucose homeostasis. Cell Rep. 2015;10(6):957–967.
   Web of Science ®Google Scholar
• Reina-San-Martin B, Chen HT, Nussenzweig A, et al. ATM is required for efficient recombination between immunoglobulin switch regions. J Exp Med. 2004;200:1103–1110.
   PubMed Web of Science ®Google Scholar
• Lumsden J, McCarty T, Petiniot L, et al. Immunoglobulin class switch recombination is impaired in ATM-deficient mice. Faseb J. 2005;19:A16–A.
   Web of Science ®Google Scholar
• Vacchio MS, Olaru A, Livak F, et al. ATM deficiency impairs thymocyte maturation because of defective resolution of T cell receptor a locus coding end breaks. P Natl Acad Sci USA. 2007;104:6323–6328.
   PubMed Web of Science ®Google Scholar
• McConville CM, Stankovic T, Byrd PJ, et al. Mutations associated with variant phenotypes in ataxia-telangiectasia. Am J Hum Genet. 1996;59:320–330.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Du LT, Tunuguntla R, et al. Functional characterization and targeted correction of ATM mutations identified in japanese patients with ataxia-telangiectasia. Hum Mutat. 2012;33:198–208.
   PubMed Web of Science ®Google Scholar
• Aurias A, Dutrillaux B, Buriot D, et al. High-frequencies of inversions and translocations of chromosomes 7 and 14 in ataxia telangiectasia. Mutat Res. 1980;69:369–374.
   PubMed Web of Science ®Google Scholar
• Meyn MS. High spontaneous intrachromosomal recombination rates in ataxia-telangiectasia. Science. 1993;260:1327–1330.
   PubMed Web of Science ®Google Scholar
• Taylor AMR. Unrepaired DNA strand breaks in irradiated ataxia telangiectasia lymphocytes suggested from cytogenetic observations. Mutat Res. 1978;50:407–418.
   PubMed Web of Science ®Google Scholar
• Gotoff SP, Amirmokri E, Liebner EJ. Ataxia telangiectasia - neoplasia untoward response to X-irradiation and tuberous sclerosis. Am J Dis Child. 1967;114:617.
   PubMedGoogle Scholar
• Morgan JL, Holcomb TM, Morrissey R. Radiation reaction in ataxia telangiectasia. Am J Dis Child. 1968;116:557.
   PubMedGoogle Scholar
• Taylor AM, Harnden DG, Arlett CF, et al. Ataxia telangiectasia: a human mutation with abnormal radiation sensitivity. Nature. 1975;258:427–429.
   PubMed Web of Science ®Google Scholar
• Gatti RA, Berkel I, Boder E, et al. Localization of an ataxia-telangiectasia gene to chromosome 11q22-23. Nature. 1988;336:577–580.
   PubMed Web of Science ®Google Scholar
• Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007;316:1160–1166.
   PubMed Web of Science ®Google Scholar
• Brown KD, Ziv Y, Sadanandan SN, et al. The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. P Natl Acad Sci USA. 1997;94:1840–1845.
   PubMed Web of Science ®Google Scholar
• Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759–769.
   PubMed Web of Science ®Google Scholar
• McKinnon PJ. ATM and the molecular pathogenesis of ataxia telangiectasia. Annu Rev Pathol-Mech. 2012;7:303–321.
   PubMed Web of Science ®Google Scholar
• Shiloh Y, Lederman HM. Ataxia-telangiectasia (A-T): an emerging dimension of premature ageing. Ageing Res Rev. 2016 May 12. pii: S1568–1637(16)30078-2. doi:10.1016/j.arr.2016.05.002. [Epub ahead of print].
   PubMedGoogle Scholar
• Watters D, Kedar P, Spring K, et al. Localization of a portion of extranuclear ATM to peroxisomes. J Biol Chem. 1999;274:34277–34282.
   PubMed Web of Science ®Google Scholar
• Zhang JW, Tripathi DN, Jing J, et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat Cell Biol. 2015;17:1259.
   PubMed Web of Science ®Google Scholar
• Valentin-Vega YA, MacLean KH, Tait-Mulder J, et al. Mitochondrial dysfunction in ataxia-telangiectasia. Blood. 2012;119:1490–1500.
   PubMed Web of Science ®Google Scholar
• Guo Z, Kozlov S, Lavin MF, et al. ATM activation by oxidative stress. Science. 2010;330:517–521.
   PubMed Web of Science ®Google Scholar
• Morita A, Tanimoto K, Murakami T, et al. Mitochondria are required for ATM activation by extranuclear oxidative stress in cultured human hepatoblastoma cell line Hep G2 cells. Biochem Bioph Res Co. 2014;443:1286–1290.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Fike F, Haghayegh S, et al. A-TWinnipeg: pathogenesis of rare ATM missense mutation c.6200C>A with decreased protein expression and downstream signaling, early-onset dystonia, cancer, and life-threatening radiotoxicity. Mol Genet Genomic Med. 2014;2:332–340.
   PubMedGoogle Scholar
• Verhagen MM, Last JI, Hogervorst FB, et al. Presence of ATM protein and residual kinase activity correlates with the phenotype in ataxia-telangiectasia: a genotype-phenotype study. Hum Mutat. 2012;33:561–571.
   PubMed Web of Science ®Google Scholar
• Barone G, Groom A, Reiman A, et al. Modeling ATM mutant proteins from missense changes confirms retained kinase activity. Hum Mutat. 2009;30:1222–1230.
   PubMed Web of Science ®Google Scholar
• Romano S, Coarelli G, Marcotulli C, et al. Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2015;14:985–991.
   PubMed Web of Science ®Google Scholar
• Pommerening H, van Dullemen S, Kieslich M, et al. Body composition, muscle strength and hormonal status in patients with ataxia telangiectasia: a cohort study. Orphanet J Rare Dis. 2015 Dec 9;10:155. doi:10.1186/s13023-015-0373-z
   PubMed Web of Science ®Google Scholar
• Voss S, Pietzner J, Hoche F, et al. Growth retardation and growth hormone deficiency in patients with ataxia telangiectasia. Growth Factors. 2014;32:123–129.
   PubMed Web of Science ®Google Scholar
• Dzieciatkowska M, Qi G, You J, et al. Proteomic characterization of cerebrospinal fluid from ataxia-telangiectasia (A-T) patients using a LC/MS-based label-free protein quantification technology. Int J Proteomics. 2011;2011:578903.
   PubMedGoogle Scholar
• Sandlund JT, Hudson MM, Kennedy W, et al. Pilot study of modified LMB-based therapy for children with ataxia-telangiectasia and advanced stage high grade mature B-cell malignancies. Pediatr Blood Cancer. 2014;61:360–362. .
   PubMed Web of Science ®Google Scholar
• Nowak-Wegrzyn A, Crawford TO, Winkelstein JA, et al. Immunodeficiency and infections in ataxia-telangiectasia. J Pediatr-Us. 2004;144:505–511.
   PubMed Web of Science ®Google Scholar
• Dournes G, Menut F, Macey J, et al. Lung morphology assessment of cystic fibrosis using MRI with ultra-short echo time at submillimeter spatial resolution. Eur Radiol. 2016; 26(11):3811–3820.
   PubMed Web of Science ®Google Scholar
• Tiddens HA, Stick SM, Wild JM, et al. Respiratory tract exacerbations revisited: ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment. Pediatr Pulmonol. 2015;50(Suppl 40):S57–S65.
   PubMed Web of Science ®Google Scholar
• Czovek D, Shackleton C, Hantos Z, et al. 2016. Tidal changes in respiratory resistance are sensitive indicators of airway obstruction in children. Thorax. Epub in press. doi:10.1136/thoraxjnl-2015-208182
   PubMed Web of Science ®Google Scholar
• Felix E, Gimenes AC, Costa-Carvalho BT. Effects of inspiratory muscle training on lung volumes, respiratory muscle strength, and quality of life in patients with ataxia telangiectasia. Pediatr Pulmonol. 2014;49:238–244.
   PubMed Web of Science ®Google Scholar
• Varon R, Demuth I, Digweed M. Nijmegen Breakage Syndrome. In: Pagon RA, Adam MP, Ardinger HH, et al., editors. GeneReviews(R). Seattle (WA): University of Washington; 1993.
   Google Scholar
• Waltes R, Kalb R, Gatei M, et al. Human RAD50 deficiency in a Nijmegen breakage syndrome-like disorder. Am J Hum Genet. 2009;84:605–616.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Levi YB, Vilozni D, et al. Neurologic presentation in children with ataxia-telangiectasia: is small head circumference a hallmark of the disease? J Pediatr-Us. 2011;159:466–U526.
   PubMed Web of Science ®Google Scholar
• Crawford TO, Mandir AS, Lefton-Greif MA, et al. Quantitative neurologic assessment of ataxia-telangiectasia. Neurology. 2000;54:1505–1509.
   PubMed Web of Science ®Google Scholar
• Jackson TJ, Chow G, Suri M, et al. Longitudinal analysis of the neurological features of ataxia-telangiectasia. Dev Med Child Neurol. 2016;58:690–697.
   PubMed Web of Science ®Google Scholar
• Woods CG, Taylor AM. Ataxia telangiectasia in the British Isles: the clinical and laboratory features of 70 affected individuals. Q J Med. 1992;82:169–179.
   PubMedGoogle Scholar
• Moin M, Aghamohammadi A, Kouhi A, et al. Ataxia-telangiectasia in Iran: clinical and laboratory features of 104 patients. Pediatr Neurol. 2007;37:21–28.
   PubMed Web of Science ®Google Scholar
• Berkun Y, Vilozni D, Levi Y, et al. Reversible airway obstruction in children with ataxia telangiectasia. Pediatr Pulm. 2010;45:230–235.
   PubMed Web of Science ®Google Scholar
• Kieslich M, Hoche F, Reichenbach J, et al. Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age. Cerebellum. 2010;9:190–197.
   PubMed Web of Science ®Google Scholar
• Ross LJ, Capra S, Baguley B, et al. Nutritional status of patients with ataxia-telangiectasia: a case for early and ongoing nutrition support and intervention. J Paediatr Child H. 2015;51:802–807. .
   PubMed Web of Science ®Google Scholar
• Stewart E, Prayle AP, Tooke A, et al. Growth and nutrition in children with ataxia telangiectasia. Arch Dis Child. 2016. doi:10.1136/archdischild-2015-310373
   PubMedGoogle Scholar
• da Silva R, Dos Santos-Valente EC, Scomparini FB, et al. The relationship between nutritional status, vitamin A and zinc levels and oxidative stress in patients with ataxia-telangiectasia. Allergol Immunopath. 2014;42:329–335.
   PubMed Web of Science ®Google Scholar
• Boder E. Ataxia-telangiectasia: an overview. Kroc Found Ser. 1985;19:1–63.
   PubMedGoogle Scholar
• Bagley J, Cortes ML, Breakefield XO, et al. Bone marrow transplantation restores immune system function and prevents lymphoma in ATM-deficient mice. Blood. 2004;104:572–578.
   PubMed Web of Science ®Google Scholar
• Ghosh S, Schuster FR, Binder V, et al. Fatal outcome despite full lympho-hematopoietic reconstitution after allogeneic stem cell transplantation in atypical ataxia telangiectasia. J Clin Immunol. 2012;32:438–440.
   PubMed Web of Science ®Google Scholar
• Ussowicz M, Musial J, Duszenko E, et al. Long-term survival after allogeneic-matched sibling PBSC transplantation with conditioning consisting of low-dose busilvex and fludarabine in a 3-year-old boy with ataxia-telangiectasia syndrome and ALL. Bone Marrow Transpl. 2013;48:740–741.
   PubMed Web of Science ®Google Scholar
• Beier R, Sykora KW, Woessmann W, et al. Allogeneic-matched sibling stem cell transplantation in a 13-year-old boy with ataxia telangiectasia and EBV-positive non-Hodgkin lymphoma. Bone Marrow Transplant. 2016;51:1271–1274.
   PubMedGoogle Scholar
• Sandoval C, Swift M. Treatment of lymphoid malignancies in patients with ataxia-telangiectasia. Med Pediatr Oncol. 1998;31:491–497.
   PubMedGoogle Scholar
• Stewart R, Kozlov S, Matigian N, et al. A patient-derived olfactory stem cell disease model for ataxia-telangiectasia. Human Molecular Genetics. 2013;22:2495–2509.
   PubMed Web of Science ®Google Scholar
• Nayler S, Gatei M, Kozlov S, et al. Induced pluripotent stem cells from ataxia-telangiectasia recapitulate the cellular phenotype. Stem Cell Transl Med. 2012;1:523–535.
   PubMed Web of Science ®Google Scholar
• Olsen JH, Hahnemann JM, Borresen-Dale AL, et al. Cancer in patients with ataxia-telangiectasia and in their relatives in the Nordic countries. J Natl Cancer I. 2001;93:121–127.
   PubMedGoogle Scholar
• Chessa L, Micheli R, Molinaro A. Focusing new ataxia telangiectasia therapeutic approaches. J Rare Disorders. 2016;2:2.
   Google Scholar
• Seidemann K, Henze G, Beck JD, et al. Non-Hodgkin’s lymphoma in pediatric patients with chromosomal breakage syndromes (AT and NBS): experience from the BFM trials. Ann Oncol. 2000;11:141–145.
   PubMed Web of Science ®Google Scholar
• Bienemann K, Burkhardt B, Modlich S, et al. Promising therapy results for lymphoid malignancies in children with chromosomal breakage syndromes (Ataxia teleangiectasia or Nijmegen-breakage syndrome): a retrospective survey. Brit J Haematol. 2011;155:468–476.
   PubMed Web of Science ®Google Scholar
• Dembowska-Baginska B, Perek D, Brozyna A, et al. Non-Hodgkin Lymphoma (NHL) in children with Nijmegen Breakage Syndrome (NBS). Pediatr Blood Cancer. 2009;52:186–190.
   PubMed Web of Science ®Google Scholar
• Patte C, Auperin A, Michon J, et al. The Societe Francaise d’Oncologie pediatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia. Blood. 2001;97:3370–3379.
   PubMed Web of Science ®Google Scholar
• Perlman SL. Cerebellar ataxia. Curr Treat Options Neurol. 2000;2:215–224.
   PubMedGoogle Scholar
• Perlman S, Becker-Catania S, Gatti RA. Ataxia-telangiectasia: diagnosis and treatment. Semin Pediatr Neurol. 2003;10:173–182.
   PubMedGoogle Scholar
• Takei A, Hamada T, Yabe I, et al. Treatment of cerebellar ataxia with 5-HT1A agonist. Cerebellum. 2005;4:211–215.
   PubMed Web of Science ®Google Scholar
• Hoche F, Seidel K, Theis M, et al. Neurodegeneration in ataxia telangiectasia: what is new? What is evident? Neuropediatrics. 2012;43:119–129.
   PubMed Web of Science ®Google Scholar
• Broccoletti T, Del Giudice E, Amorosi S, et al. Steroid-induced improvement of neurological signs in ataxia-telangiectasia patients. Eur J Neurol. 2008;15:223–228.
   PubMed Web of Science ®Google Scholar
• Russo I, Cosentino C, Del Giudice E, et al. In ataxia-teleangiectasia betamethasone response is inversely correlated to cerebellar atrophy and directly to antioxidative capacity. Eur J Neurol. 2009;16:755–759.
   PubMed Web of Science ®Google Scholar
• Broccoletti T, Del Giudice E, Cirillo E, et al. Efficacy of very-low-dose betamethasone on neurological symptoms in ataxia-telangiectasia. Eur J Neurol. 2011;18:564–570.
   PubMed Web of Science ®Google Scholar
• Zannolli R, Buoni S, Betti G, et al. A randomized trial of oral betamethasone to reduce ataxia symptoms in ataxia telangiectasia. Movement Disord. 2012;27:1312–1316.
   PubMed Web of Science ®Google Scholar
• Chessa L, Leuzzi V, Plebani A, et al. Intra-erythrocyte infusion of dexamethasone reduces neurological symptoms in ataxia teleangiectasia patients: results of a phase 2 Trial. Orphanet J Rare Dis. 2014;9:5. doi:10.1186/1750-1172-9-5
   PubMed Web of Science ®Google Scholar
• Leuzzi V, Micheli R, D’Agnano D, et al. Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia. Neurol Neuroimmunol Neuroinflamm. 2015;2:e98.
   PubMed Web of Science ®Google Scholar
• Biagiotti S, Menotta M, Orazi S, et al. Dexamethasone improves redox state in Ataxia Telangiectasia cells by promoting NRF2-mediated antioxidant response. FEBS J. 2016. doi:10.1111/febs.13901
   PubMedGoogle Scholar
• Nissenkorn A, Borgohain R, Micheli R, et al. Development of global rating instruments for pediatric patients with ataxia telangiectasia. Eur J Paediatr Neuro. 2016;20:140–146.
   PubMed Web of Science ®Google Scholar
• Nissenkorn A, Hassin-Baer S, Lerman SF, et al. Movement disorder in ataxia-telangiectasia: treatment with amantadine sulfate. J Child Neurol. 2013;28:155–160.
   PubMed Web of Science ®Google Scholar
• Yorek MA, Dunlap JA, Manzo-Fontes A, et al. Abnormal myo-inositol and phospholipid metabolism in cultured fibroblasts from patients with ataxia telangiectasia. Biochim Biophys Acta. 1999;1437:287–300.
   PubMed Web of Science ®Google Scholar
• Adams BR, Hawkins AJ, Povirk LF, et al. ATM-independent, high-fidelity nonhomologous end joining predominates in human embryonic stem cells. Aging (Albany NY). 2010;2:582–596.
   PubMedGoogle Scholar
• Fukawatase Y, Toyoda M, Okamura K, et al. Ataxia telangiectasia derived iPS cells show preserved x-ray sensitivity and decreased chromosomal instability. Sci Rep-Uk. 2014;4. Article number: 5421. doi:10.1038/srep05421
   PubMed Web of Science ®Google Scholar
• Li HL, Gee P, Ishida K, et al. Efficient genomic correction methods in human iPS cells using CRISPR-Cas9 system. Methods. 2016;101:27–35.
   PubMed Web of Science ®Google Scholar
• Yusa K, Rashid ST, Strick-Marchand H, et al. Targeted gene correction of alpha(1)-antitrypsin deficiency in induced pluripotent stem cells. Nature. 2011;478:391.
   PubMed Web of Science ®Google Scholar
• Keeling KM, Wang D, Conard SE, et al. Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol. 2012;47:444–463.
   PubMed Web of Science ®Google Scholar
• Du LT, Damoiseaux R, Nahas S, et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med. 2009;206:2285–2297.
   PubMed Web of Science ®Google Scholar
• Du LT, Jung ME, Darnoiseaux R, et al. A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene. Mol Ther. 2013;21:1653–1660.
   PubMed Web of Science ®Google Scholar
• Reichenbach J, Schubert R, Schindler D, et al. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Sign. 2002;4:465–469.
   PubMed Web of Science ®Google Scholar
• Reliene R, Schiestl RH. Experimental antioxidant therapy in ataxia telangiectasia. Clin Med Oncol. 2008;2:431–436.
   PubMedGoogle Scholar
• Gueven N, Luff J, Peng C, et al. Dramatic extension of tumor latency and correction of neurobehavioral phenotype in ATM-mutant mice with a nitroxide antioxidant. Free Radical Bio Med. 2006;41:992–1000.
   PubMed Web of Science ®Google Scholar
• Reliene R, Fleming SM, Chesselet MF, et al. Effects of antioxidants on cancer prevention and neuromotor performance in ATM deficient mice. Food Chem Toxicol. 2008;46:1371–1377.
   PubMed Web of Science ®Google Scholar
• Schubert R, Erker L, Barlow C, et al. Cancer chemoprevention by the antioxidant tempol in ATM-deficient mice. Hum Mol Genet. 2004;13:1793–1802.
   PubMed Web of Science ®Google Scholar
• Chin T, Alonazi N B-cell and T-cell combined disorders medication 2014. Available from: http://emedicine.medscape.com/article/885493-medication#showall
   Google Scholar
• Chen WT, Ebelt ND, Stracker TH, et al. ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion. Elife. 2015;4. doi:10.7554/eLife.07270
   Web of Science ®Google Scholar
• Yang Y, Hui CW, Li JL, et al. The Interaction of the ATM Genotype with inflammation and oxidative stress (vol 9, e85863, 2014). Plos One. 2014. Jan 20;9(1):e85863. doi:10.1371/journal.pone.0085863. eCollection 2014.
   Web of Science ®Google Scholar
• Kamsler A, Daily D, Hochman A, et al. Increased oxidative stress in ataxia telangiectasia evidenced by alterations in redox state of brains from ATM-deficient mice. Cancer Res. 2001;61:1849–1854.
   PubMed Web of Science ®Google Scholar
• Chen P, Peng C, Luff J, et al. Oxidative stress is responsible for deficient survival and dendritogenesis in Purkinje neurons from ataxia-telangiectasia mutated mutant mice. J Neurosci. 2003;23:11453–11460.
   PubMed Web of Science ®Google Scholar
• Paull TT, Lee JH, Ditch S, et al. Mechanisms of ATM activation. Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr SY11-03. doi:10.1158/1538-7445.AM2012-SY11-03.
   Google Scholar
• Rai P, Parrish M, Tay IJJ, et al. Streptococcus pneumoniae secretes hydrogen peroxide leading to DNA damage and apoptosis in lung cells. P Natl Acad Sci USA. 2015;112:E3421–E3430.
   PubMed Web of Science ®Google Scholar
• Quick KL, Dugan LL. Superoxide stress identifies neurons at risk in a model of ataxia-telangiectasia. Ann Neurol. 2001;49:627–635.
   PubMed Web of Science ®Google Scholar
• Kim J, Wong PKY. Oxidative stress is linked to ERK1/2-p16 signaling-mediated growth defect in ATM-deficient astrocytes. J Biol Chem. 2009;284:14396–14404.
   PubMed Web of Science ®Google Scholar
• McDonald CJ, Ostini L, Wallace DF, et al. Iron loading and oxidative stress in the ATM(-/-) mouse liver. Am J Physiol-Gastr L. 2011;300:G554–G60.
   PubMed Web of Science ®Google Scholar
• Shackelford RE, Fu YM, Manuszak RP, et al. Iron chelators reduce chromosomal breaks in ataxia-telangiectasia cells. DNA Repair. 2006;5:1327–1336.
   PubMed Web of Science ®Google Scholar
• Winterbourn CC. Toxicity of iron and hydrogen peroxide: the Fenton reaction. Toxicol Lett. 1995;82–3:969–974.
   Web of Science ®Google Scholar